Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (...
This acquisition expands Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organization This acquisition expands Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organi...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Talaris Therapeutics, Inc. (NasdaqGM: TALS) with Tourmaline Bio, Inc. pursuant to which Talaris shareholders will end up owning approximately 21.3% of the combined company, each on a fully diluted basis. KSF is ...
Navigating the world of penny stocks can often feel like a dance, full of rhythm, calculated movements, and unexpected twists. One of the popular styles in this domain is swing trading, a strategy where investors profit from the ‘swing' or fluctuations in stock prices over a short period.
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline's anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)
BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned wo...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.